Renalytix appoints Dan Levangie to its Board of Directors

– UK, London / USA, NY –  Renalytix Plc (LON: RENX | NASDAQ: RNLX) today announced the appointment of Dan Levangie to its board of directors.

“Dan brings extensive commercial experience to Renalytix as we begin implementing our KidneyIntelX national marketing strategy to over 200,000 primary care physicians treating an estimated 12 million diabetic kidney disease patients insured by the Government Services Administration, Medicare and Medicare Advantage programs,” said CEO, James McCullough. “He has set a standard for broad-scale up of impactful diagnostic products in the oncology and diabetes markets that will be core to the Renalytix strategy.”

Mr. Levangie is also joining the remuneration committee.

About Dan Levangie

Mr. Levangie is an experienced executive and long-serving board director in the diagnostics and medical devices industry. He is co-founder and manager of ATON Partners, a private investment firm, and president and CEO of CereVasc, LLC, a medical device company. He also has served on the board of directors of Exact Sciences Corporation (NASDAQ: EXAS) since 2010. From 2013 through January 2017, Mr. Levangie served as president of Insulet Drug Delivery Systems and served as a lead director of Insulet Corporation. From 2011 through 2013, Mr. Levangie was CEO of Dune Medical Devices, Inc., and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013. Previously, Mr. Levangie held executive management positions with Cytyc Corporation including EVP and COO, CEO and president until the acquisition of Cytyc by Hologic, in 2007. He served on the board of Hologic from 2007 to 2009.

“I’m excited to join the Renalytix team as we bring this important innovation to the market. To be involved in the early commercial scale-up and execution of the Renalytix national marketing strategy will be a major step forward for the company and early-stage patients at risk of future kidney failure, where we can have the greatest impact on improving outcomes and reducing costs. We intend to have a significant impact on the course of the disease of these patients,” said Mr. Levangie.

About Renalytix

Renalytix is the global founder and leader in the new field of bioprognosis for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product is KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration, and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team